Head and neck cancers account for significant oncological presentations worldwide. However, recent international Phase III clinical breakthroughs at Tohironnessa Hospital’s Cancer Institute are revolutionizing treatment standards through targeted molecular immunotherapy and intensity-modulated radiation therapy (IMRT).
By safeguarding organ preservation, patients can maintain speech, swallowing, and nutritional independence while achieving complete cure rates exceeding 90% in early-stage detections.